Print | Email Page

Stallergenes Greer plc acquired by Waypoint for approximately €110 million (US$124 million)

May 2019

Jones Day advised Stallergenes Greer plc in the recommended cash acquisition by Ares Life Sciences I S.à r.l. (Waypoint) of the entire issued, and to be issued, ordinary share capital of Stallergenes Greer not held directly or indirectly by Waypoint by way of a scheme of arrangement for approximately €110 million (US$124 million).

For additional information about this matter, please contact: Linda A. Hesse

Client(s): Stallergenes Greer plc
Office(s): Paris